Waiting to Reprogram Your Cells? Don’t Hold Your Breath
March 16, 2017
(Scientific American) – They can also give rise, however, to potentially dangerous mutations, possibly including ones that lead to cancerous tumors. Thus, iPS cells are a double-edged sword—their great promise is tempered by risk. Another problem is the high cost of treating a patient with his or her own newly reprogrammed cells. But now Japanese researchers are trying a different approach.